Program
olaparib
Also written as “Olaparib”, “AZD2281” and “KU-0059436 (AZD2281)(PARP inhibitor)”.
Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms · Prostatic Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 6 companies.
Drug pageOlaparib: every studyMany companies study it; this page follows only the 76 they lead. All 323 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 5915 open or running | phase 4since Jun 10, 2015 | Jun 27, 2007 | Apr 6, 2027phase 3 · NCT04421963 |
| Merckits history only | 125 open or running | phase 3since Mar 29, 2018 | Aug 3, 2016 | May 5, 2027phase 3 · NCT04380636 |
| Novartisits history only | 20 open or running | phase 3since Jan 25, 2021 | Jan 25, 2021 | none ahead |
| Boryung Pharmaceuticalits history only | 11 open or running | phase 1since Jul 7, 2025 | Jul 7, 2025 | none ahead |
| CSPC Pharmaceutical Groupits history only | 10 open or running | phase 1since Apr 7, 2024 | Apr 7, 2024 | none ahead |
| Daewoong Pharmaceuticalits history only | 11 open or running | phase 1since Jan 19, 2026 | Jan 19, 2026 | Mar 2027phase 1 · NCT07371104 |
Also a collaborator on its studies: Myriad Genetic Laboratories, Frontier Science & Technology Research Foundation, Hoffmann-La Roche, Myriad Genetics, Iqvia Pty, Covance, Theradex, Parexel and KuDOS Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Jun 27, 2007.
- Mar 12, 2018Phase 3 study in Ovarian NeoplasmsNCT03534453 · 225 enrolled · China, Malaysia
- May 14, 2018Phase 1 study in Malignant Solid TumorNCT03553108 · 18 enrolled · Belgium
- Sep 28, 2018Phase 3 study in Metastatic Castration-resistant Prostate CancerNCT03732820 · 895 enrolled · United States, Australia, Belgium and more
- Oct 15, 2018Phase 3 study in Ovarian NeoplasmsNCT03737643 · 1,407 enrolled · United States, Austria, Belgium and more
- Nov 27, 2018Phase 2 study in Non-small Cell Lung Cancer NSCLCNCT03775486 · 401 enrolled · United States, Belgium, Hungary and more
- Nov 13, 2019Phase 1 study in NeoplasmsNCT04236414 · 16 enrolled · Denmark, France, Germany and more
- Jan 21, 2020Phase 2 study in Ovarian NeoplasmsNCT04239014 · United States, Canada, Italy and more
- Feb 10, 2020Phase 3 study in Endometrial NeoplasmsNCT04269200 · 805 enrolled · United States, Australia, Belgium and more
- Mar 30, 2020Phase 4 study in Ovarian NeoplasmsNCT04330040 · 202 enrolled · India
- May 19, 2020Phase 3 study in Ovarian NeoplasmsNCT04421963 · 185 enrolled · United States, Belgium, Bulgaria and more
- Apr 20, 2021Phase 3 study in Ovarian NeoplasmsNCT04884360 · 366 enrolled · Chile, China, Colombia and more
- Dec 20, 2021Phase 3 study in Metastatic Castration-resistant Prostate CancerNCT05171816 · 110 enrolled · China
- Jul 5, 2022Phase 2 study in Breast NeoplasmsNCT05498155 · 50 enrolled · United States, Australia, Austria and more
- Jul 11, 2022Phase 4 study in Metastatic Castration-resistant Prostate CancerNCT05457257 · 43 enrolled · China
Ahead
- Apr 6, 2027Primary completion: phase 3 study in Ovarian NeoplasmsNCT04421963
TargetBeta
“PARP 1, 2 and 3 inhibitor”ChEMBL 37, by rule
Studies
All 59 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05457257Metastatic Castration-resistant Prostate Cancer · China | 4 | Active, not recruiting | Oct 22, 2024 | 43 |
| NCT05498155Breast Neoplasms · United States, Australia, Austria and more | 2 | Completed | Nov 20, 2024 | 50 |
| NCT05171816Metastatic Castration-resistant Prostate Cancer · China | 3 | Active, not recruiting | Jan 22, 2024 | 110 |
| NCT04884360Ovarian Neoplasms · Chile, China, Colombia and more | 3 | Active, not recruiting | Jul 27, 2026 | 366 |
| NCT04421963Ovarian Neoplasms · United States, Belgium, Bulgaria and more | 3 | Active, not recruiting | Apr 6, 2027 | 185 |
| NCT04330040Ovarian Neoplasms · India | 4 | Completed | Sep 30, 2022 | 202 |
| NCT04269200Endometrial Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Jul 8, 2024 | 805 |
| NCT04239014Ovarian Neoplasms · United States, Canada, Italy and more | 2 | Withdrawn | Jan 25, 2021 | 0 |
| NCT04236414Neoplasms · Denmark, France, Germany and more | 1 | Completed | Feb 4, 2025 | 16 |
| NCT03775486Non-small Cell Lung Cancer NSCLC · United States, Belgium, Hungary and more | 2 | Active, not recruiting | Jan 11, 2021 | 401 |
| NCT03737643Ovarian Neoplasms · United States, Austria, Belgium and more | 3 | Active, not recruiting | Mar 17, 2025 | 1,407 |
| NCT03732820Metastatic Castration-resistant Prostate Cancer · United States, Australia, Belgium and more | 3 | Active, not recruiting | Jul 30, 2021 | 895 |
| NCT03553108Malignant Solid Tumor · Belgium | 1 | Completed | Mar 12, 2019 | 18 |
| NCT03534453Ovarian Neoplasms · China, Malaysia | 3 | Completed | Jan 27, 2025 | 225 |
| NCT03459846Urinary Bladder Neoplasms · United States, Canada, Russia and more | 2 | Active, not recruiting | Oct 15, 2020 | 154 |
| NCT03402841Ovarian Neoplasms · Austria, Belgium, Bulgaria and more | 3 | Completed | Oct 2, 2020 | 279 |
| NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more | 2 | Active, not recruiting | Sep 13, 2024 | 528 |
| NCT03286842HER2-ve Metastatic Breast Cancer · United States, Bulgaria, Canada and more | 3 | Completed | Oct 8, 2021 | 256 |
| NCT03106987Carcinoma, Ovarian Epithelial · Belgium, Canada, Denmark and more | 3 | Completed | Feb 15, 2021 | 220 |
| NCT03022409Squamous Cell Carcinoma of Head and Neck · United States, France, Taiwan | 1 | Completed | Jan 20, 2021 | 21 |
| NCT02987543Metastatic Castration-resistant Prostate Cancer · United States, Argentina, Australia and more | 3 | Completed | Jun 4, 2019 | 387 |
| NCT02983799Ovarian Neoplasms · United States, Canada | 2 | Completed | Dec 3, 2020 | 272 |
| NCT02561832Breast Neoplasms · United States, Spain | 1 | Terminated | Sep 30, 2016 | 15 |
| NCT02476968BRCA or HRR+ Mutated Ovarian Cancer Patients · Bulgaria, Canada, Czechia and more | 4 | Completed | Apr 17, 2020 | 181 |
| NCT02430311Advanced Solid Tumours · China | 1 | Completed | Jul 27, 2016 | 36 |
| NCT02392676Ovarian Neoplasms · United States, Korea, Republic of, Peru and more | 3 | Withdrawn | Jun 2019 | 0 |
| NCT02282020Ovarian Neoplasms · United States, Argentina, Belgium and more | 3 | Completed | Oct 10, 2018 | 266 |
| NCT02184195Pancreatic Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Jan 15, 2019 | 154 |
| NCT02093351Neoplasms · Belgium, Denmark, France and more | 1 | Completed | Apr 30, 2015 | 79 |
| NCT02032823Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 27, 2020 | 1,837 |
| NCT02000622Breast Neoplasms · United States, Bulgaria, China and more | 3 | Completed | Dec 9, 2016 | 302 |
| NCT01972217Prostatic Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Sep 22, 2017 | 158 |
| NCT01924533Stomach Neoplasms · China, Japan, Korea, Republic of and more | 3 | Completed | Apr 4, 2016 | 525 |
| NCT01921140Neoplasms · Belgium, Denmark, Netherlands and more | 1 | Completed | Apr 8, 2014 | 60 |
| NCT01874353Ovarian Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Sep 19, 2016 | 327 |
| NCT01851265Neoplasms · Belgium, Netherlands, United Kingdom | 1 | Completed | Oct 18, 2013 | 32 |
| NCT01844986Pathologic Complete Response · United States, Australia, Brazil and more | 3 | Active, not recruiting | May 17, 2018 | 450 |
| NCT01813474Neoplasms · Japan | 1 | Completed | Aug 31, 2016 | 23 |
| NCT01078662Ovarian · United States, Australia, Germany and more | 2 | Completed | Jul 31, 2012 | 298 |
| NCT01081951Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Active, not recruiting | Oct 10, 2011 | 162 |
| NCT01063517Stomach Neoplasms · Korea, Republic of | 2 | Completed | May 11, 2012 | 124 |
| NCT00912743Colorectal Neoplasms · United States | 2 | Completed | Mar 2012 | 33 |
| NCT00819221Solid Tumors · Italy, Switzerland | 1 | Terminated | Nov 30, 2011 | 44 |
| NCT00782574Advanced Solid Tumors · United States, Spain | 1 | Completed | Feb 1, 2012 | 57 |
| NCT00777582Solid Tumors · Australia, Belgium, Switzerland and more | 1 | Active, not recruiting | Feb 6, 2009 | 197 |
| NCT00753545Ovarian Neoplasms · United States, Australia, Austria and more | 2 | Completed | Jun 30, 2010 | 265 |
| NCT00710268Neoplasm Metastasis · United Kingdom | 1 | Completed | Mar 2009 | 18 |
| NCT00707707Breast Neoplasms · Australia, Austria, Belgium and more | 1 | Completed | Nov 9, 2009 | 19 |
| NCT00679783Ovarian Neoplasms · Canada | 2 | Completed | Mar 26, 2010 | 99 |
| NCT00633269Neoplasm Metastasis · United Kingdom | 1 | Completed | Oct 2008 | 6 |
| NCT00628251Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Sep 15, 2009 | 97 |
| NCT00572364Neoplasms · Japan | 1 | Completed | Mar 2009 | 18 |
| NCT00516802Melanoma Neoplasms · United States, United Kingdom | 1 | Completed | Jan 2009 | 40 |
| NCT00516724Triple Negative Metastatic Breast Cancer · Belgium, Netherlands, United Kingdom | 1 | Completed | Jan 4, 2013 | 189 |
| NCT00516438Malignant Solid Tumors · United Kingdom | 1 | Completed | Mar 2009 | 48 |
| NCT00516373Ovarian Neoplasms · Belgium, Netherlands, Poland and more | 1 | Completed | Dec 17, 2008 | 98 |
| NCT00515866Pancreatic Neoplasms · United States, United Kingdom | 1 | Completed | Oct 2011 | 68 |
| NCT00494442Ovarian Neoplasms · United States, Australia, Germany and more | 2 | Completed | Mar 17, 2009 | 58 |
| NCT00494234Breast Neoplasms · United States, Australia, Canada and more | 2 | Completed | Feb 27, 2009 | 54 |
How it is read
Names in the registry
- “Olaparib”, 38 entries
- “olaparib”, 10 entries
- “AZD2281”, 10 entries
- “KU-0059436 (AZD2281)(PARP inhibitor)”, 10 entries
- “Olaparib 300mg tablets”, 3 entries
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 24 studies
- Breast Neoplasms, 7 studies
- Prostatic Neoplasms, 7 studies
- Neoplasms, 6 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.